Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

Palatin Technologies, Inc. ( NYSE: PTN) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ET Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary ...

Eli Lilly has filed lawsuits against three companies for continuing to sell compounded versions of tirzepatide, the active ingredient in its weight loss and type 2 diabetes meds Zepbound and Mounjaro.

Shares of Air Canada finished up just 0.1 per cent after it said on Wednesday it would increase direct flights between Canada ...

Folwell’s staff forecasted in July the plan will be $816 million in the red by calendar year 2027 ... Saxenda and Zepbound, and laid out the approach they would take to do so.

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...